Regeneron Pharmaceuticals Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Regeneron Pharmaceuticals

REGN 754.49

-3.3%

Feb 10 3:59 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Miljenko Zuanic who wrote (636)	4/19/2002 10:34:40 PM
From: scaram(o)uche	Read Replies (1) of 3561

axiombio.com Obesity and related diseases are a worldwide epidemic. In the U.S. alone, approximately 20% of men and 25% of women are obese and are at substantially increased risk for type 2 diabetes, coronary heart disease and hypertension. Currently approved treatments for obesity are only modestly effective and exhibit side-effects. The naturally occurring protein CNTF has been tested in humans and causes weight loss without provoking “rebound” eating after cessation of treatment. However, patient compliance with this therapy is expected to be low because CNTF is a protein and must, therefore, be administered by daily injections. We are developing Physiogenomics-based approaches and unique medicinal chemistry strategies for identification of an orally active, small molecule mimic of CNTF.

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next